FLT3 inhibitorFDA-approvedInvestigational
Gilteritinib
How it works
Blocks the FLT3 tyrosine kinase enzyme, which is overactive in AML cells, disrupting cancer cell growth and survival signals.
Cancer types
Leukemia— FLT3-ITD-positive AML
Efficacy
In clinical trials, around 50% of AML patients achieved a complete or partial response, with a median progression-free survival of approximately 8 months.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Gilteritinib with Ivosidenib or Enasidenib for Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Testing Gilteritinib and Momelotinib for Relapsed or Refractory Acute Myeloid Leukemia | Leukemia | phase-1 | — | Source → |
| Comparing Gilteritinib and Midostaurin in Acute Myeloid Leukemia | Leukemia | phase-2 | — | Source → |
| Testing SNDX-5613 and Gilteritinib for Leukemia Treatment | Leukemia | phase-1 | — | Source → |
| New Trial for Acute Myeloid Leukemia Patients Explores Alternative Treatments | Leukemia | phase-3 | — | Source → |
| Gilteritinib May Help Overcome Resistance to Lung Cancer Treatment | Lung Cancer | lab-study | — | Source → |
| Testing a New Treatment for Relapsed or Refractory AML with FLT3 Mutation | Leukemia | phase-3 | — | Source → |
| Testing Gilteritinib for Advanced ALK-positive Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Gilteritinib Therapy After Transplantation for High-Risk AML Patients | Leukemia | meta-analysis | 1- and 2-year overall survival rates ranged from 72.3% to 100% and 55.8% to 60.0%, respectively. | Source → |
| Gilteritinib May Help Treat Prostate Cancer | Prostate Cancer | lab-study | — | Source → |
| New Cancer Treatment Shows Promise with Low Heart Damage | Leukemia | lab-study | — | Source → |
| Rare Eye Condition Linked to Cancer Treatment | Leukemia | observational | — | Source → |
| Combining Metformin and Gilteritinib May Improve Leukemia Treatment | Leukemia | lab-study | Metformin plus gilteritinib (low dose) dramatically suppressed leukemia progression and prolonged survival in FLT3-ITD AML mouse models. | Source → |
| Rare Skin Reaction Linked to Leukemia Treatment | Leukemia | observational | — | Source → |
| Rare Bleeding Side Effect Found in Cancer Patients Taking Gilteritinib | Leukemia | observational | — | Source → |
| Itraconazole Affects Gilteritinib Levels in the Body | Leukemia | animal-study | — | Source → |
| Gilteritinib Enhances Leukemia-Fighting Effects in Transplant Patients | Leukemia | animal-study | — | Source → |
| New Combination Therapies Identified for Rare Leukemia | Leukemia | lab-study | — | Source → |
| Gilteritinib Cost-Effective for Relapsed Acute Myeloid Leukemia | Leukemia | phase-3 | — | Source → |
| New Treatment Option for Leukemia Patients | Leukemia | phase-3 | Multiple clinical trials demonstrated higher response rates of complete remission or complete remission with partial hematologic recovery and longer overall survival compared with patients treated with salvage chemotherapy. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.